Abstract: Purified BMP-3 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
March 4, 1991
Date of Patent:
August 13, 2002
Assignee:
Genetics Institute, Inc.
Inventors:
Elizabeth A. Wang, John M. Wozney, Vicki Rosen
Abstract: Osteoinductive pharmaceutical formulations comprising antifibrinolytic agents such as epsilon amino acid caproic acid or other lysine analogues or serine protease inhibitors and cartilage and/or bone inductive proteins are disclosed. These formulations are useful in the treatment of cartilage and/or bone defects.
Type:
Grant
Filed:
June 18, 1990
Date of Patent:
November 15, 1994
Assignee:
Genetics Institute, Inc.
Inventors:
Tobin N. Gerhart, Elizabeth A. Wang, Mary J. Kriz
Abstract: A method for purifying erythropoietin is described. The method comprises treating partially purifying erythropoietin by reverse phase high performance liquid chromatography to obtain homogeneous erythropoietin having a molecular weight of about 34,000 daltons on SDS PAGE and moving a single peak on reverse phase HPLC. The homogeneous erythropoietin protein preferably has a specific activity of at least 120,000 IU, more preferably at least 160,000 IU per absorbance unit at 280 nm.
Abstract: The invention provides novel DNA and peptide sequences encoding a family of phospholipase A.sub.2 enzymes, with specific activities of approximately 20 .mu.mol/min/mg in the mixed micelle assay. These enzymes are useful in methods for detecting the anti-inflammatory potential of various chemical agents. The invention also details novel methods for determining such potential using the novel sequences, methods for making the novel peptides, and methods for developing new anti-inflammatory drugs.
Abstract: An improved process for producing recombinant bone-inducing protein of the BMP-2 family as described. A suitable mammalian host cell transformed with a DNA encoding the protein is cultured in an appropriate culture medium to which is added about 10 to 1000 .mu.g/ml dextran sulfate. The presence of dextran sulfate in the medium results in an increased yield of recombinant bone-inducing protein.
Abstract: This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.
Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for reducing or removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.
Abstract: The invention described encompasses an isolated DNA sequence encoding all or a portion thereof of a cell surface receptor for murine and human erythropoietin (hereinafter EPO-R), along with the isolated polypeptide expressed by the DNA sequence (i.e., isolated EPO-R). The invention also encompasses host cells containing the above-described DNA sequence, preferably, host cells which express the polypeptide encoded by the DNA sequence (EPO-R) at a significantly higher level than that produced by normal red blood cell precursors. The invention further encompasses DNA sequences encoding secreted forms of the human EPO-R and polypeptides corresponding thereto. The EPO-receptor in all of the disclosed forms can be used as models for designing drugs or in pharmaceutical compositions for treating anemias.
Type:
Grant
Filed:
March 25, 1991
Date of Patent:
January 11, 1994
Assignees:
Genetics Institute, Inc., Whitehead Institute for Biomedical Research, The Children's Medical Center Corporation
Inventors:
Alan D'Andrea, Gordon G. Wong, Simon S. Jones
Abstract: This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.
Abstract: The present invention provides a process for increasing the rate of production of carbon dioxide, ethanol and other fermentation products such as citric acid, produced by yeast such as Saccharomyces cerevisiae during fermentation, and decreasing biomass production by regulating the rate of glycolysis indirectly through changing the energy balance of the cell, i.e., by reducing intracellular ATP levels. Modifications for so altering the glycolysis rate involve the use of either a regulated ATP hydrolysis within the cell or a regulated leakage of ATP from the cell.
Abstract: Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.
Abstract: An improved method for producing Factor VIII:c-type proteins is disclosed which involves culturing mammalian cells which are capable of expressing the protein. In accordance with this invention the cells are cultured in a medium containing an effective amount of a substance comprising (a) von Willebrand Factor-type protein, (b) a phospholipid or phospholipid mixture, or a mixture of (a) and (b).
Abstract: A transformation vector containing a heterologous product gene and two or more different heterologous selectable amplifiable marker genes is described. Preferably, the marker genes form a polycistronic transcription unit. Also described is a method for obtaining high level expression of a desired protein by culturing eukaryotic cells containing the vectors of the invention.
Abstract: A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.
Type:
Grant
Filed:
May 21, 1990
Date of Patent:
June 1, 1993
Assignee:
Genetics Institute, Inc.
Inventors:
Frances K. Bennett, Stephen R. Paul, Yu-Chung Yang
Abstract: A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound healing and related tissue repair.
Type:
Grant
Filed:
May 12, 1989
Date of Patent:
May 18, 1993
Assignees:
Genetics Institute, Inc., Dana Farber Cancer Inst.
Inventors:
Barrett Rollins, Charles Stiles, Gordon G. Wong
Abstract: Disclosed herein is the treatment of patients suffering from AIDS-type disease with erythropoietin alone or together with a colony stimulating factor, and/or an anti-viral agent and/or IL-2.
Abstract: Purified BMP-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
March 7, 1990
Date of Patent:
February 16, 1993
Assignee:
Genetics Institute, Inc.
Inventors:
John M. Wozney, Elizabeth A. Wang, Vicki A. Rosen, Anthony J. Celeste
Abstract: Purified BMP-2 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
July 11, 1989
Date of Patent:
November 24, 1992
Assignee:
Genetics Institute, Inc.
Inventors:
Elizabeth A. Wang, John M. Wozney, Vicki A. Rosen
Abstract: Purified BMP-7 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartlage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
November 17, 1989
Date of Patent:
August 25, 1992
Inventors:
Vicki A. Rosen, Elizabeth A. Wang, John M. Wozney
Abstract: Homogeneous K-FGF and a process for its production are provided. Also provided are pharmaceutical compositions for use in treating soft tissue injuries and musculo-skeletal disorders in mammals and methods of treatment. The purification of the bacterially produced K-FGF comprises reduction of a salt solution containing K-FGF to effect the precipitation of the product.
Type:
Grant
Filed:
November 16, 1989
Date of Patent:
June 30, 1992
Assignee:
Genetics Institute, Inc.
Inventors:
David T. Rogers, Neil M. Wolfman, Jasbir S. Seehra